Medadvisor media and news thread, page-23

I saw on market index yesterday, I think Morgans was analyst & it had a reduced price target from 55c to 40c for mdr with a BUY recommendation which at reduced price still implies based on the current share price more than a 100% return potentially with current SP being at 19.5c. I'm not sure if the price falling has ended yet but feel these are bargain levels given that we are still supposedly going to be ebitda + for the yr & were at these SP levels before even being ebitda +, so overdone imo

GLTAH